SCHEMBL26110488

SCHEMBL26110488

Cn1ccc2c(N3CCCC3)cc(Cl)nc21

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NCF1 P14598 3/20 0.39
HRH4 Q9H3N8 1/20 0.39
PKM P14618 1/20 0.36
ALOX15 P16050 1/20 0.36
CASP1 P29466 1/20 0.36
HSD17B10 Q99714 1/20 0.36
KDM4E B2RXH2 2/20 0.35
CHKA P35790 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
ALDH1A1 P00352 3/20 0.35
POLB P06746 1/20 0.35
MAT2A P31153 2/20 0.33
ALDH1A3 P47895 1/20 0.33
LMNA P02545 1/20 0.33
HTT P42858 1/20 0.33
METAP1 P53582 1/20 0.33
NPC1 O15118 1/20 0.33
RAB9A P51151 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
CYP1A2 P05177 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30611850 1.00 NCF1 (0.39) NCF1HRH4PKMALOX15CASP1
SCHEMBL30612141 0.75 NPC1 (0.39) NCF1KDM4ECHKAALDH1A1POLB
SCHEMBL26106359 0.75 NPC1 (0.39) NCF1KDM4ECHKAALDH1A1POLB
SCHEMBL22024527 0.75 HRH4 (0.36) HRH4LMNA
SCHEMBL29697245 0.75 HRH4 (0.36) HRH4LMNA
SCHEMBL30611959 0.74 HRH4 (0.33) HRH4
SCHEMBL26106777 0.74 HRH4 (0.33) HRH4
SCHEMBL30503534 0.74 KDM4E (0.41) HRH4KDM4EPOLBLMNAHTT
SCHEMBL26631311 0.74 KDM4E (0.41) HRH4KDM4EPOLBLMNAHTT
SCHEMBL30612107 0.73 POLB (0.41) HSD17B10KDM4EPOLBHTTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250214991-A1 BICYCLIC HETEROARYL-CONTAINING COMPOUNDS AS IKZF2 DEGRADERS ONCOPIA THERAPEUTICS, INC. D/B/A/ SK LIFE SCIENCE LABS 2025-07-03 US disclosed
EP-4499629-A1 BICYCLIC HETEROARYL-CONTAINING COMPOUNDS AS IKZF2 DEGRADERS Oncopia Therapeutics, Inc. D/B/A SK Life Science Labs (US) 2025-02-05 EP disclosed
WO-2023183919-A1 BICYCLIC HETEROARYL-CONTAINING COMPOUNDS AS IKZF2 DEGRADERS ONCOPIA THERAPEUTICS, INC. D/B/A PROTEOVANT THERAPEUTICS, INC. (US) 2023-09-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250214991-A1 BICYCLIC HETEROARYL-CONTAINING COMPOUNDS AS IKZF2 DEGRADERS IKZF1, IKZF2, IKZF3 NCF1 1409/4885HRH4 4461/4885PKM 1664/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.